Objectives: The aldosterone-to-renin ratio (ARR) is commonly used in the screening of primary aldosteronism. However, limited information is available with regard to the intra-patient variability in this ratio. Our objective is to determine whether ARR measurements are reliably consistent over both the short- and long-term.

Methods: We assessed the short-term variability of the aldosterone-to-renin ratio in 116 unmedicated, essential hypertensive participants who had two blood samples taken in the morning of the same day for measurement of aldosterone and active plasma renin concentration. Long-term variability was studied in 22 unmedicated, essential hypertensive participants who had two blood samples taken approximately 1 year apart. All samples were taken under highly standardized conditions.

Results: Our data show that renin, aldosterone and the aldosterone-to-renin ratio show marked variations, both when measured on the same day and when assessed at a longer interval. The ARR becomes increasingly variable as its mean value increases. Its degree of variability is similar in both the short-term and the long-term.

Conclusions: Based on our findings, we conclude that the aldosterone-to-renin has acceptable short-term variability in the lower ranges, but increasingly dubious reliability as aldosterone-to-renin values rise. Thus, in a clinical context, great caution should be taken in interpreting point-measurements of moderate to high aldosterone-to-renin ratio values.

Download full-text PDF

Source
http://dx.doi.org/10.1097/HJH.0000000000003257DOI Listing

Publication Analysis

Top Keywords

aldosterone-to-renin ratio
20
primary aldosteronism
8
short-term variability
8
unmedicated essential
8
essential hypertensive
8
hypertensive participants
8
participants blood
8
blood samples
8
aldosterone-to-renin
7
variability
6

Similar Publications

Introduction: The clinical biochemical characteristics and target organ damage (TOD) in patients with plasma aldosterone concentrations (PAC) ranging from 50 to 100 ng/L after a saline infusion test (SIT) have not been fully studied.

Methods: A total of 611 hypertensive patients with an elevated aldosterone-to-renin ratio (ARR) who underwent a supine SIT at Henan Provincial People's Hospital were enrolled. The patients were divided into three groups according to their post-SIT PAC: <50 ng/L (control group), 50-100 ng/L (indeterminate post-SIT results group), and >100 ng/L (PA group).

View Article and Find Full Text PDF

Diagnosis of Primary Aldosteronism without Discontinuation of Interfering Antihypertensive Medications.

Curr Hypertens Rep

December 2024

Department of Endocrinology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88, Jiefang Road, Shangcheng District, Hangzhou, 310000, China.

Purpose Of Review: One of the challenges in the diagnosis and management of primary aldosteronism (PA), the most common type of secondary hypertension with curative potential, is the modification of antihypertensive medications. We seek to explore whether these medications can be continued during the diagnostic process of PA to minimize the duration and risks associated with medication adjustments.

Recent Findings: We searched PubMed for eligible original literature between 1990 and 2024 using the following keywords: (screening) AND (primary aldosteronism); (confirmatory) AND (primary aldosteronism); (adrenal vein sampling) AND primary aldosteronism).

View Article and Find Full Text PDF

Diagnostic efficacy of aldosterone-to-renin ratio to screen primary aldosteronism in hypertension: a systemic review and meta-analysis.

Ther Adv Endocrinol Metab

December 2024

Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, No. 579, Sec. 2, Yunlin Road, Douliu City, Yunlin 640, Taiwan.

Background: The aldosterone-to-renin ratio (ARR) is commonly used for screening primary aldosteronism (PA) in patients with difficult-to-control hypertension. Various thresholds have been proposed for the confirmatory tests, leading to inconsistency in the results.

Objectives: This study aimed to elucidate the performance of ARR screening in hypertensive patients.

View Article and Find Full Text PDF

Percutaneous microwave ablation for aldosterone-producing adenoma.

J Vasc Interv Radiol

December 2024

Department of Radiology, Tianjin Medical University General Hospital, Anshan Road 154#, Heping District, Tianjin, 300052, China. Electronic address:

Thirty-five patients diagnosed with aldosterone-producing adenomas underwent CT-guided percutaneous microwave ablation (MWA). Comparisons of aldosterone-to-renin ratio (ARR), potassium level, blood pressure (BP), and medications were performed preoperatively, postoperatively, and at the latest follow-up examination. The outcome assessment was based on the primary aldosteronism surgical outcome (PASO) Standards.

View Article and Find Full Text PDF

[Value of 24-hour urinary aldosterone in diagnosis and classification of primary hyperaldosteronism].

Zhonghua Yi Xue Za Zhi

December 2024

Department of Endocrinology, Third Xiangya Hospital, Central South University, Changsha410013, China.

Article Synopsis
  • The study aimed to evaluate the effectiveness of 24-hour urinary aldosterone (UEA) for diagnosing and classifying primary aldosteronism (PA) among 282 hypertensive patients admitted to a university hospital between December 2020 and December 2023.
  • After excluding patients with secondary hypertension, 243 subjects were analyzed, revealing a distinction between PA (135 patients) and primary hypertension (108 patients) based on the causes of their hypertension.
  • Findings showed that specific measurements like serum potassium and plasma renin activity were significantly lower in the PA group compared to the primary hypertension group, indicating potential biomarkers for PA diagnosis and classification.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!